Novartis study highlights benefits of Cosentyx in treating psoriasis

Novartis has announced new clinical trial data that demonstrates the benefits Cosentyx can offer in the treatment of psoriasis.

The head-to-head CLARITY study compared the performance of Cosentyx to an established alternative therapy, revealing that Novartis' drug was more effective in delivering clear or almost clear skin among adults with moderate-to-severe plaque psoriasis at 12 weeks.

Cosentyx is the first and only fully human interleukin-17A inhibitor that has shown sustained skin clearance rates at five years among patients enrolled in a phase III psoriasis study, with these findings backing up those seen in the prior CLEAR study.

To date, Cosentyx has been used by more than 125,000 patients worldwide, and has been consistently associated with a favourable safety profile.

Dr Mark Lebwohl, chairman of the Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai Hospital, said: "With these findings, clinicians can have even greater confidence including Cosentyx in their treatment plans."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.